文献速递造血干细胞移植与细胞治疗白血病

c-MPL为肿瘤靶向T细胞受体转基因T细胞提供共刺激和细胞因子信号

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.
PubMed 文献 · Blood · 2017-10-27

研究将血小板生成素受体c-MPL转入T细胞,利用肿瘤微环境中的TPO或FDA批准的c-MPL激动剂提供共刺激和细胞因子信号。c-MPL+多克隆T细胞在TPO刺激下扩增,在免疫缺陷人TPO转基因小鼠中过继转移后持久存活;在TCR转基因T细胞中c-MPL激活增强抗肿瘤功能、扩增和细胞因子产生,保留中央记忆表型,并增强体内抗白血病活性,机制涉及1型干扰素通路。

要点

  • c-MPL转基因使T细胞对TPO产生扩增和增殖反应,过继转移后持久存活。
  • 在TCR转基因T细胞中c-MPL激活增强抗肿瘤功能、扩增和细胞因子产生,保留中央记忆表型。
  • c-MPL信号增强连续杀伤、免疫突触形成和体内抗白血病活性,机制涉及1型干扰素通路。

核心结论

  • 作者提出一种新型免疫治疗策略:使用c-MPL增强的转基因T细胞,响应内源性TPO(血液恶性肿瘤中的微环境因子)或c-MPL靶向药理制剂。

研究设计与样本

  • 研究将c-MPL转基因导入T细胞,在免疫缺陷人TPO转基因小鼠中进行过继转移实验,并在白血病异种移植模型中评估体内抗白血病活性。

主要发现

  • c-MPL+多克隆T细胞在TPO刺激下扩增和增殖,在免疫缺陷人TPO转基因小鼠中过继转移后持久存活。
  • 在TCR转基因T细胞中,c-MPL激活增强抗肿瘤功能、T细胞扩增和细胞因子产生,并保留中央记忆表型。
  • c-MPL信号使连续肿瘤细胞杀伤成为可能,增强有效免疫突触形成,并在白血病异种移植模型中改善体内抗白血病活性。
  • 研究确定1型干扰素通路为c-MPL在T细胞中介导免疫刺激的分子机制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on host-derived costimulation and cytokine signals for their full and sustained activation. However, in patients with cancer, both signals are frequently impaired. Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. Thus, we hypothesized that host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-engineered TCR-transgenic T cells. We found that c-MPL+ polyclonal T cells expand and proliferate in response to TPO, and persist longer after adoptive transfer in immunodeficient human TPO-transgenic mice. In TCR-transgenic T cells, c-MPL activation enhances antitumor function, T-cell expansion, and cytokine production and preserves a central memory phenotype. c-MPL signaling also enables sequential tumor cell killing, enhances the formation of effective immune synapses, and improves antileukemic activity in vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced transgenic T cells responding to either endogenously produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-targeted pharmacological agents.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nishimura CD, Brenner DA, Mukherjee M, et al. c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood. 2017. PMID: 29079582. doi:10.1182/blood-2017-02-769463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。